ArticlePharmacoEconomics2021

The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States.

Anita J Brogan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.